- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2018-04-03 16:09:53
- Reporting Period:
- Accepted Time:
- 2018-04-03 16:09:53
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1488613||Foundation Medicine Inc.||FMI||Services-Medical Laboratories (8071)||271316416|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1710939||J Michael Doherty||C/o Foundation Medicine, Inc. |
150 Second Street
Cambridge MA 02141
|Head Of Product Development||No||Yes||No||No|
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
- Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018.
- Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2017 in Table I of the Form 3 filed on July 5, 2017. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale.